Catalyst Pharmaceuticals Reports Positive Phase 1 Study Results for Vamorolone, Demonstrating Glucocorticoid Activity Without Immunosuppression at Clinical Doses

Catalyst Pharmaceuticals announced topline results from a two-part Phase 1 study of vamorolone in healthy adults. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses. The findings suggest that vamorolone delivers glucocorticoid and anti-inflammatory activity without significant immunosuppressant effects, supporting its potential use in treating chronic inflammatory rare diseases.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has reported topline results from a two-part Phase 1 clinical trial of vamorolone, a novel dissociative corticosteroid, in healthy adult volunteers. The study evaluated the drug’s corticosteroid activity, cortisol suppression, and immunosuppressive effects at clinical doses. Findings indicate that vamorolone demonstrated balanced glucocorticoid and anti-inflammatory activity, with expected cortisol suppression and no significant immunosuppressive effects observed. These results support the drug’s potential as a treatment for chronic inflammatory rare diseases, where minimizing immunosuppression is a key therapeutic goal.

Vamorolone is already approved in the U.S. for the treatment of Duchenne muscular dystrophy (DMD) under the brand name AGAMREE®. The drug was granted FDA approval in October 2023 and is marketed in North America by Catalyst, which holds exclusive commercial rights to the therapy. AGAMREE has also received Orphan Drug and Rare Pediatric Disease designations, qualifying it for seven years of orphan drug exclusivity. The compound is protected by patents extending exclusivity until 2040.

The Phase 1 findings align with earlier clinical data from the VISION-DMD trial, which demonstrated vamorolone’s long-term efficacy and favorable safety profile in pediatric DMD patients. The 48-week study showed that vamorolone maintained motor function improvements and reversed some of the bone-related side effects associated with traditional corticosteroids like prednisone. These results reinforce the drug’s differentiated mechanism of action and its potential to offer a safer alternative to conventional corticosteroids in rare disease populations.

Catalyst, a commercial-stage biopharmaceutical company, has a portfolio of therapies targeting rare and difficult-to-treat diseases. In addition to AGAMREE, the company markets FIRDAPSE® and FYCOMPA® for Lambert-Eaton myasthenic syndrome and epilepsy. The company’s recent expansion into new therapeutic areas and its focus on high-quality, patient-centric drug development position it to continue growing its rare disease franchise.

The Phase 1 results represent another milestone in the development of vamorolone and could support further clinical exploration in additional rare inflammatory conditions. Investors will be watching for updates on the drug’s commercial performance and potential expansion into new indications.